items. Comparative scores and profiles on the other psychopathological measures e.g. ScI-90-R, GHQ-30 and PSE (10, item) supported validation. Some items were more sensitive to change over time.

Conclusion: Practical and comparative ratings encompassing grief, and with numerical scoring for use in any circumstances (and to monitor change) can aid comparative studies of bereavement.

MELATONIN SECRETION IN SEASONAL AFFECTIVE DISORDER

T. Partonen, J. Lönnqvist. Department of Mental Health, National Public Health Institute, Mannerheimintie 160, FIN-00300 Helsinki, Finland

Background. Seasonal affective disorder (SAD) has been related to abnormal melatonin metabolism and treated with exposure to artificial light for 3-6 hours a day. Our objectives were to test the following hypotheses on SAD patients: there would be, first, phase and amplitude abnormalities in the circadian rhythm of melatonin secretion; second, abnormalities in the onset and offset timing of melatonin secretion; and third, abnormal suppression of melatonin levels by light.

Method. The diagnosis was assessed with the Diagnostic and Statistical Manual of Mental Disorders (III-R/IV). All patients suffered from winter SAD and were drug-free. Samples of saliva were collected from 12 patients every other hour for 24 hours, waking the patient at night, from 16 patients and 13 healthy controls every hour between 20.00 and 24.00 hours as well as 06.00 and 08.00 hours, and from 11 patients and 10 healthy controls at 22.00 and 23.00 hours respectively. On light tests, the subjects were exposed to fluorescent light of 3300 lux at 22.00 hours for 5 minutes and 1 hour respectively during two consecutive evenings. We expected that only the latter would lead to the suppression. The subjects were treated with equal light for 1 hour for 5 mornings, for 1 hour for 14 mornings, and for 1/2 hour for 14 evenings respectively in winter. The second and third protocols were repeated in summer, without exposing the subjects to light.

The samples of saliva were collected in a dark room, thereafter immediately frozen until analysed for melatonin by radioimmunoassay. The best fitting cosinor function was adjusted to the circadian data by using the least squares method. The subjects rated their level of subjective sleepiness with the Stanford Sleepiness Scale and with the Visual Analogue Scale simultaneously with the collection of the samples in each experiment.

Results. There was no significant difference in the mean levels of melatonin or the suppression of melatonin levels in saliva by light between the patients and controls. The treatment with morning light as well as the first light test reduced significantly more the evening level of subjective sleepiness in the patients than in the controls. This reduction correlated with the clinical improvement in the former experiment but was not associated with the change in melatonin secretion in either experiment. In spite of the good antidepressive response observed among the patients, bright light treatment did not result in any significant change in the phase or the amplitude of the circadian rhythm of melatonin secretion, the mean or peak evening and morning melatonin concentrations, or the degree of suppression of melatonin levels by light.

Conclusions. We suggest against the melatonin hypothesis that the antidepressive effect of bright light treatment is not explained by abnormal melatonin secretion or excessive sensitivity to light among SAD patients. The effect of light on mechanisms regulating the level of sleepiness deserves further study. In addition, the duration of exposure to light required daily for effective treatment is shorter than claimed in the literature.

NR16. Psychopharmacology of affective disorders

Chairmen: C Thompson, K Abel

A COMPARISON OF PAROXETINE AND IMIPRAMINE IN SIX MONTHS CONTINUATION THERAPY POST ECT

P. Bech, L. Lauritzen, K. Odgaard, L. Clemmensen, M. Lund, J. Ohrstöm, C. Black. Frederiksborg General Hospital, Department of Psychiatry, DK-3400 Hillerød, Denmark

The results to be presented are part of a comprehensive study [1] including psychopathological structure analysis and placebo treatment of the subgroup of patients with electrocardiological impairments in whom imipramine was contraindicated.

In total 27 patients were randomized to paroxetine in a dose of 30 mg daily and 25 patients to imipramine in a dose of 150 mg daily. No difference between the two groups of patients was found concerning age (mean: 60 years), sex, co-morbid medical disorders (about 30%), number of ECT treatments (mean 11) or duration of convulsions (mean 46 seconds).

In the post ECT or 6 months continuation phase, paroxetine was significantly more effective than imipramine. Thus, 12% of the patients relapsed in the paroxetine treated group and 30% relapsed in the imipramine treated group (P < 0.05). In comparison 65% of the patients relapsed in the placebo treated group. It should be emphasized that the mean dose of imipramine in the continuation phase was 140 mg daily leading to plasma concentrations of 448 nmol/l of imipramine and desipramine.

It was not possible clinically to increase the imipramine dose due to intolerable side-effects. However, no difference in plasma levels was obtained between patients who relapsed and patients not relapsing, either in the imipramine nor in the paroxetine treated groups.

In conclusion, paroxetine was found superior to imipramine in relapse prevention after ECT therapy of major depression.

[1] Lauritzen L et al, Acta Psychiatr Scand 1996 (in press).

PHARMACOLOGICAL EVIDENCE THAT DEPRESSIVE SYMPTOMS DO NOT SHARE A COMMON SEROTONERGIC MECHANISM ACROSS DIAGNOSES

A.J. Cleare, K.M. Abel, V. O'Keane. Department of Psychological Medicine, Institute of Psychiatry, London

It has recently been suggested by Van Praag (1990) that there may be psychopathological dimensions, such as depressive symptomatology, which share common biological correlates independent of psychiatric diagnosis. We investigated this possibility in patients with major depression (n = 19), schizophrenia (n = 13) and depression secondary to hypothyroidism (n = 10). Subjects underwent assessment with the 17-item Hamilton Rating Scale for Depression and the Montgomery-Asberg Depression Rating Scale in order to obtain a dimensional measure of depressive symptoms. Central serotonergic function was assessed using the prolactin and cortisol (CORT) responses to dfenfluramine, a specific serotonin (5-HT) releasing agent. Healthy, non-depressed matched control subjects were included in the analyses to correct for age, sex, weight and menstrual cycle phase. Depressive symptoms in major depression (r = -0.53, P = 0.01) and hypothyroidism (r = -0.73, P = 0.003) were inversely related to CORT responses. In contrast, depressive symptoms in schizophrenia were positively related to CORT responses (r = 0.62, P = 0.03).